<DOC>
	<DOCNO>NCT00006257</DOCNO>
	<brief_summary>RATIONALE : Drugs SU5416 may stop growth cancer stop blood flow tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining SU5416 chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine SU5416 paclitaxel treat patient advanced cancer .</brief_summary>
	<brief_title>SU5416 Paclitaxel Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose SU5416 combine paclitaxel patient advanced malignancy . - Determine toxicity pharmacokinetics regimen patient . - Determine effect regimen variety histological molecular biomarkers angiogenesis , include vitro activity assay endothelial cell proliferation , migration , invasion . OUTLINE : This dose escalation study SU5416 . Patients receive SU5416 IV 1 hour twice weekly first week . During subsequent course , SU5416 administer day 1 , 4 , 8 , 11 , 15 , 18 , 22 , 25 . Paclitaxel begin second week therapy administer IV 1 hour day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SU5416 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 24 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven advanced malignancy satisfactory treatment exists Must tumor accessible biopsy Minimum 1 baseline biopsy require No brain metastasis primary CNS tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : SGOT SGPT less 2 time upper limit normal unless due presence tumor Bilirubin normal Renal : Creatinine great 1.5 mg/dL Creatinine clearance great 60 mL/min Cardiovascular : No uncompensated coronary artery disease ECG physical examination No myocardial infarction severe unstable/angina within past 6 month No severe peripheral vascular disease associate diabetes mellitus No severe deep vein arterial thrombosis within past 3 month Pulmonary : No pulmonary embolism within past 3 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No unstable severe concurrent medical condition No active uncontrolled infection No history allergic reaction paclitaxel Cremophor No great grade 1 peripheral neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior SU5416 Chemotherapy : No prior paclitaxel Greater 4 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : Greater 4 week since prior radiotherapy recover Surgery : See Disease Characteristics Other : Recovered prior investigational agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>